- Home
- RVMD vs ZBH Comparison
RVMD vs ZBH Comparison
Compare RVMD & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | ZBH |
|---|---|---|
| Founded | 2014 | 1927 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 19.5B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | RVMD | ZBH |
|---|---|---|
| Price | $141.21 | $83.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 21 |
| Target Price | ★ $140.84 | $101.00 |
| AVG Volume (30 Days) | ★ 3.7M | 2.4M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.55 |
| Revenue | N/A | ★ $8,231,500,000.00 |
| Revenue This Year | N/A | $4.96 |
| Revenue Next Year | $533.02 | $3.76 |
| P/E Ratio | ★ N/A | $23.12 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $34.00 | $79.83 |
| 52 Week High | $155.70 | $108.29 |
Technical Indicators
Market Signals| Indicator | RVMD | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 35.80 |
| Support Level | $93.39 | N/A |
| Resistance Level | $155.70 | $96.94 |
| Average True Range (ATR) | 7.33 | 2.72 |
| MACD | -0.52 | -1.34 |
| Stochastic Oscillator | 40.96 | 21.75 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.